Szefler Stanley J, Apter Andrea
Division of Clinical Pharmacology, Department of Pediatrics, National Jewish Medical and Research Center, Denver, Colo 80206, USA.
J Allergy Clin Immunol. 2005 Mar;115(3):470-7. doi: 10.1016/j.jaci.2004.12.1123.
Last year's review on adult and pediatric asthma highlighted reports related to asthma genetics, the importance of upper airway management, the costs of asthma, and the importance of early recognition and intervention. This year we will organize our discussion to review recent reports related to the origins and persistence of asthma in both adults and children. We highlight Journal publications from 2004, along with recent key publications from other medical journals, to provide a perspective on the rapidly developing areas of genetics, including pharmacogenetics, respiratory infection, biomarker measurements, and asthma pharmacotherapy. This new understanding of the pathogenesis of asthma combined with clinical applications of genetics and biomarkers should lead to new management strategies. Asthma management is likely to change in the coming years from a strategy directed to the best outcome in groups of patients to an individualized approach to assessment and management.
去年对成人和儿童哮喘的综述强调了与哮喘遗传学、上呼吸道管理的重要性、哮喘的成本以及早期识别和干预的重要性相关的报告。今年,我们将组织讨论,回顾有关成人和儿童哮喘的起源和持续存在的最新报告。我们重点介绍了2004年以来《期刊》上的出版物,以及其他医学期刊最近的重要出版物,以提供有关遗传学快速发展领域的观点,包括药物遗传学、呼吸道感染、生物标志物测量和哮喘药物治疗。对哮喘发病机制的这种新认识,结合遗传学和生物标志物的临床应用,应该会带来新的管理策略。未来几年,哮喘管理可能会从针对一组患者的最佳结果的策略转变为个体化的评估和管理方法。